Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. J Michael Dixon (jmd@wght.demon.co.uk), consultant surgeon
  1. Academic Office, Edinburgh Breast Unit, Western General Hospital, Edinburgh EH4 2XU

    EDITOR—Two contrasting leading articles followed publication of the randomised trial of the women's health initiative study of hormone replacement therapy. 1 2

    Stevenson and Whitehead in the BMJ said that the increased risk of breast cancer in the study was small, but they did not mention that during the study 42% of women taking active drug and 38% receiving placebo stopped the assigned treatment.1

    In contrast, Fletcher and Colditz reported in JAMA that the intention to treat analysis may have underestimated the …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular